Foghorn Therapeutics (FHTX) Registration Filing summary

Company overview and business model

• Clinical-stage precision therapeutics biotechnology company focused on correcting abnormal gene expression by targeting the chromatin regulatory system, with primary applications in oncology and potential in other diseases.

• Utilizes a proprietary Gene Traffic Control platform to identify, validate, and drug targets within the chromatin regulatory system, aiming to pioneer a new class of precision medicines.

• Incorporated in Delaware in October 2015, with headquarters in Cambridge, Massachusetts.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, preclinical and clinical development, commercialization, acquisitions or in-licensing, collaborations, working capital, and capital expenditures.

• Management retains broad discretion over allocation of net proceeds.

Risk factors and disclosures

• Investment involves a high degree of risk, including risks detailed in the latest Annual Report and other SEC filings incorporated by reference.

• Risks include clinical, regulatory, competitive, operational, and economic uncertainties, as well as forward-looking statement limitations.